Biocartis announced it successfully completed an EUR 64.5 million equity fundraising, one of the largest private rounds in the European life sciences industry in recent years. The additional capital will fund the commercial roll-out of IdyllaTM in Europe later this year, and the expansion of its commercial reach beyond Europe as of next year. Furthermore, the fundraising will also support and accelerate the development of a wide range of diagnostic tests for IdyllaTM. With this round, the total capital invested in Biocartis to date amounts to EUR 240 million (approx. USD 316 million).
